Abivax

Today, Abivax announced its 2026 corporate outlook, highlighting new market insights, clinical progress, and advances in our therapeutic pipeline. Updates include: ☑️ New market insights indicate significant future expansion of the ulcerative colitis (UC) market, with obefazimod well positioned to become a future market leader in the IBD space ☑️ ABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on December 18, 2025, found no new safety signals with over 80% of participants having completed the 44-week double blind maintenance trial ☑️ ABTECT-UC Phase 3 maintenance topline results expected late Q2 2026, with a subsequent US regulatory filing planned for late 2026 ☑️ ENHANCE-CD Phase 2b induction trial of obefazimod in moderate-to-severely active Crohn’s disease (CD) ongoing; induction results expected late 2026 ☑️ 22 abstracts accepted for upcoming February 2026 European Crohn’s and Colitis Organization (ECCO) conference including oral presentation of obefazimod impact on fibrosis in in-vitro and preclinical models ☑️ Cash runway expected into Q4 2027, after full debt reimbursement in Q4 2025 The company looks forward to discussing these exciting updates in San Francisco next week. Read more in our press release: https://bit.ly/3L7OOCd

Happy holidays from all of us at Abivax. As we reflect on the past year, we’re grateful for our teams, partners, and the broader IBD community who inspire our mission. Wishing everyone a healthy and joyful season. 

Today Abivax announced the acceptance of 22 abstracts on obefazimod in IBD at #ECCO2026 including new preclinical anti-fibrotic findings. The data will be shared across multiple sessions, underscoring the robustness of the obefazimod evidence base. Read more in the press release: https://lnkd.in/eHYzXaBm

Today we announced Q3 financial results and shared updates that reflect our continued progress throughout the quarter. Read more in the press release here: https://lnkd.in/eN-wSFsj

Awareness is a catalyst for change, and this Crohn's & Colitis Foundation’s Awareness Week, we’re reaffirming our commitment to the scientific rigor and innovation needed to move the field forward. Chris Rabbat underscores the importance of taking action to help improve the lives of people living with ulcerative colitis (UC) and Crohn’s disease. At Abivax, that mission guides our research every day.

Abivax is proud to be recognized with three distinctions at this year’s European Lifestars Awards: CEO of the Year (Marc de Garidel), Biotech of the Year, and Post-IPO Raise of the Year. These honors underscore our continued growth and leadership as we harness the power of microRNA biology to create transformative treatments for patients with chronic inflammatory diseases. We are grateful to our team, partners, and stakeholders for their unwavering support. Congratulations to all who participated, and to everyone who continues to drive innovation forward alongside us.

Today we announced patient-reported outcomes data from our Phase 3 ABTECT induction trials of obefazimod, demonstrating significant improvements in quality of life (#QoL) for people living with moderate-to-severely active #UlcerativeColitis. Read more: https://lnkd.in/eNs5CQRH

Today we announced patient-reported outcomes data from our Phase 3 ABTECT induction trials of obefazimod, demonstrating significant improvements in quality of life (#QoL) for people living with moderate-to-severely active #UlcerativeColitis. Read more: https://lnkd.in/eNs5CQRH

The Abivax team was proud to participate in #BIOEurope 2025, joining global leaders in #biopharma innovation and partnership. Abivax CEO Marc de Garidel joined Board member Kinam Hong, M.D., MBA, CFA, Partner at Sofinnova, to share how Abivax is advancing its #UlcerativeColitis and #CrohnsDisease programs designed to transform the treatment of chronic inflammatory diseases. With continued innovation and collaboration, Abivax remains committed to delivering meaningful progress for people living with chronic inflammatory diseases worldwide.